Olfactory neuroblastoma (esthesioneuroblastoma) is a rare neuroectodermal malignant tumor arising from the olfactory neuroepithelium. It accounts for approximately 3-6% of all sinonasal malignancies and shows a bimodal age distribution (second and sixth decades). It originates from the cribriform plate and classically exhibits a dumbbell-shaped growth pattern extending through the anterior cranial fossa + nasal cavity. The Kadish staging system (A: nasal cavity confined, B: paranasal sinus extension, C: beyond sinuses, D: distant metastasis) and Hyams histopathological grading (I-IV) are prognostic determinants. Bone destruction at the cribriform plate level on CT and prominent enhancement with peritumoral cystic component (on the anterior cranial fossa side — 10-30%) on MRI are characteristic findings. Treatment involves craniofacial resection + radiotherapy ± chemotherapy. Overall 5-year survival is 60-80%, 10-year 40-60%, varying by stage and histological grade.
Age Range
10-70
Peak Age
50
Gender
Equal
Prevalence
Rare
Olfactory neuroblastoma arises from olfactory neuroepithelial stem cells localized at the cribriform plate level in the nasal cavity roof. These neuroepithelial cells have both neuronal and epithelial differentiation capacity, and the tumor reflects these bipotential characteristics. Histologically, Homer-Wright rosettes (neuroblastic differentiation) and Flexner-Wintersteiner rosettes (primitive neuroepithelial structures) may be seen. The tumor erodes the cribriform plate to show intracranial extension into the anterior cranial fossa, creating the classic dumbbell configuration — the large component in the nasal cavity connects with the small intracranial component through the cribriform plate defect. The peritumoral cystic component (in 10-30% of cases) forms on the anterior cranial fossa side of the tumor as a result of reactive arachnoid granulation and CSF accumulation in the subarachnoid space; this cyst is a reactive rather than tumoral structure and shows CSF signal. High-grade tumors (Hyams III-IV) show more aggressive behavior, higher cellularity, and more prominent mitotic activity; these histological features translate to low ADC on DWI and high FDG uptake on PET-CT.
A dumbbell-shaped, intensely enhancing mass originating from the cribriform plate with intranasal and intracranial (anterior cranial fossa) components, together with a CSF signal cystic component at the superior aspect of the intracranial component, is a highly characteristic combination for olfactory neuroblastoma.
Bone destruction at the cribriform plate level is seen on CT. Destruction typically involves one or both sides of the cribriform plate and may extend to the fovea ethmoidalis. The bone defect determines that the tumor shows intracranial extension and is Kadish stage C. Coronal reformatted images best evaluate cribriform plate integrity. In advanced cases, the ethmoid roof, anterior cranial fossa floor, and planum sphenoidale may also be involved. A soft tissue density mass in the superior nasal cavity and ethmoid sinuses is seen accompanying bone destruction. CT also evaluates orbital invasion (lamina papyracea destruction) and sphenoid sinus involvement.
Report Sentence
Bone destruction at the cribriform plate level is noted with intracranial extension into the anterior cranial fossa; consistent with Kadish stage C.
On contrast-enhanced T1-weighted sequences, olfactory neuroblastoma demonstrates intense, generally homogeneous solid enhancement. This intense enhancement reflects the high vascularity of the tumor. Characteristically, a non-enhancing cystic component may be seen at the superior or lateral margin of the intracranial component (in 10-30% of cases). This peritumoral cyst shows CSF signal (T1 hypointense, T2 hyperintense) and is a reactive rather than tumoral structure. Tumor-cyst differentiation on contrast-enhanced MRI is critical: the tumor enhances intensely while the cyst does not enhance. Dural enhancement indicates intracranial extension and dural invasion; olfactory bulb enhancement indicates tumor involvement. The size of the intracranial component and its relationship to the brain parenchyma are determinants in surgical planning.
Report Sentence
On contrast-enhanced T1 sequences, the mass demonstrates intense homogeneous solid enhancement with a non-enhancing cystic component seen superiorly to the intracranial component.
On T2-weighted sequences, olfactory neuroblastoma shows intermediate to hyperintense signal. The solid tumoral component generally shows intermediate signal while the peritumoral cystic component shows very hyperintense signal isointense to CSF. These two different signal components (solid tumor + cystic component) create the characteristic appearance of the tumor. In high-grade tumors (Hyams III-IV), more heterogeneous T2 signal may be seen and necrotic areas may appear as hyperintense foci. T2 sequence also helps evaluate olfactory bulb involvement, orbital invasion, and brain edema/invasion.
Report Sentence
On T2-weighted sequences, the solid tumoral component shows intermediate signal with a cystic component showing CSF signal superior to the tumor in the anterior cranial fossa.
On DWI, olfactory neuroblastoma shows variable diffusion restriction related to histological grade. In low-grade tumors (Hyams I-II), mild to moderate restriction (ADC 1.0-1.3 × 10⁻³ mm²/s) may be seen; in high-grade tumors (Hyams III-IV), marked restriction (ADC <0.8 × 10⁻³ mm²/s) may be seen. The peritumoral cystic component may show T2 shine-through on DWI but shows high signal on the ADC map (no restriction — CSF). ADC values may be helpful in predicting histological grade and assessing treatment response.
Report Sentence
Mild/moderate/marked diffusion restriction is noted in the solid tumoral component on DWI with ADC values measured at approximately ... × 10⁻³ mm²/s; the peritumoral cystic component does not show restriction.
On contrast-enhanced CT, olfactory neuroblastoma demonstrates avid homogeneous enhancement reflecting the tumor's rich vascularity. Enhancement is generally homogeneous with minimal heterogeneity possibly seen in large tumors. Contrast-enhanced CT provides preliminary assessment of tumor size and extent and should be interpreted together with bone destruction. Relationship with vascular structures (anterior cerebral artery, anterior ethmoidal artery) is evaluated for surgical planning. Cervical lymph node metastasis occurs in 5-20% and should be evaluated with neck CT.
Report Sentence
On contrast-enhanced CT, the mass demonstrates avid homogeneous enhancement; extension into the anterior cranial fossa is present with bone destruction at the cribriform plate level.
Criteria
Tumor confined to nasal cavity, no sinus extension.
Distinct Features
Best prognosis, 5-year survival >80%. Usually small, cribriform plate intact.
Criteria
Tumor extends to paranasal sinuses, does not extend beyond sinuses.
Distinct Features
Ethmoid sinuses most commonly involved sinus. 5-year survival 60-70%.
Criteria
Intracranial extension with cribriform plate destruction, orbital invasion, or distant metastasis.
Distinct Features
Most common stage (60-70% at presentation). Dumbbell configuration and peritumoral cyst seen at this stage. 5-year survival 40-60%.
Distinguishing Feature
Melanoma shows melanin-related T1 hyperintense signal (ONB T1 hypointense/intermediate), originates from septum/inferior turbinate (ONB from cribriform plate), does not show peritumoral cyst, and is T2 hypointense except for amelanotic variant.
Distinguishing Feature
SCC more commonly originates from maxillary sinus (ONB from cribriform plate), shows heterogeneous enhancement (ONB homogeneous), does not show peritumoral cyst, does not show dumbbell configuration, and exhibits more aggressive bone destruction.
Distinguishing Feature
Lymphoma shows very low ADC (<0.6), homogeneous moderate enhancement, exhibits 'bone replacement' pattern rather than bone destruction, does not show dumbbell configuration or peritumoral cyst, usually presents as diffuse midline nasal cavity thickening.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
İlk 5 yıl 6 ayda bir MRG + göğüs BT; 5-15 yıl arası yıllık takip. Servikal lenf nodu metastazı riski nedeniyle boyun değerlendirmesi dahil edilmelidir.Craniofacial resection (endoscopic or open) + adjuvant radiotherapy is the standard approach in olfactory neuroblastoma treatment. In advanced stage (Kadish C) and high-grade (Hyams III-IV) tumors, neoadjuvant or adjuvant chemotherapy (cisplatin + etoposide) is added. Preoperative CT is required for bone anatomy and MRI for intracranial extension, dural invasion, orbital invasion, and peritumoral cyst evaluation. Cervical lymph node metastasis (5-20%) usually appears late and elective neck radiotherapy may be considered in high stage/grade tumors. Late recurrence (>5 years) is possible and requires long-term follow-up.
Treatment of olfactory neuroblastoma is craniofacial resection + radiotherapy ± chemotherapy. Kadish staging (A-D) determines prognosis. Intracranial extension (Kadish C) carries worse prognosis. 5-year survival is 60-80% (early stage). Late local recurrence and cervical metastasis may occur — requires long-term follow-up.